Table 1 Characteristics of included studies
Author, publication year | Setting | Sample size (n) | Intervention (n of patients) | Comparator (n of patients) | Important patient outcomes |
|---|---|---|---|---|---|
Desai et al. 2015 [23] | Kenya | n = 1546 | IPT DP (n = 516) | IPT SP (n = 515) IST DP (n = 515) | Incidence of SAEs |
Mlugu et al. 2021 [33] | Tanzania | n = 956 | IPT DP (n = 478) | IPT SP (n = 478) | Prevalence of vomiting within 30 min after study drug administration |
Kajubi et al. 2019 [10] | Uganda | n = 782 | IPT DP (n = 391) | IPT SP (n = 391) | Mean change in QTc interval Incidence of SAEs Incidence of grade 3 or 4 AEs possibly related to study drug Prevalence of vomiting within30 minutes after study drug administration |
Kakuru et al. 2016 [24] | Uganda | N = 300 | IPT DP 3 doses (n = 94) IPT DP Monthly (n = 100) | IPT SP 3 doses (n = 106) | Median change in QTc interval Incidence of SAEs Incidence of grade 3 or 4 AEs possibly related to study drug Prevalence of vomiting within 30 min after study drug administration |
Natureeba et al. 2017 [32] | Uganda | n-200 | IPT DP Monthly + TMP/SMX Daily (n = 100) | TMP/SMX Daily(n = 100) | Mean change in QTc interval Incidence of SAEs Prevalence of vomiting within 30 min after study drug administration |
Madanitsa et al. 2023 [34] | Kenya, Malawi, Tanzania | N = 4680 | IPT DP (n = 1561) IPT DP + Azithromycin (1558) | IPT SP (n = 1561) | Incidence of SAEs Vomiting within 30 min after study drug administration |